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Peroxisome proliferator-activated receptor-γ (PPARγ), a ligand-activated transcription factor, has 
protective roles in the cerebral circulation and is highly activated during pregnancy. Thus, we 
hypothesized that PPARγ is involved in the adaptation of cerebral vasculature to pregnancy. Non-
pregnant (NP) and late-pregnant (LP) rats were treated with a specific PPARγ inhibitor GW9662 
(10 mg/kg/day, in food) or vehicle for 10 days and vascular function and structural remodeling 
were determined in isolated and pressurized posterior cerebral arteries (PCA). Expression of 
PPARγ and angiotensin type 1 receptor (AT1R) in cerebral (pial) vessels was determined by 
real-time RT-PCR. PPARγ inhibition decreased blood pressure and increased blood glucose 
in NP rats, but not in LP rats. PPARγ inhibition reduced dilation to acetylcholine and sodium 
nitroprusside in PCA from NP (p < 0.05 vs. LP-GW), but not LP rats. PPARγ inhibition tended 
to increase basal tone and myogenic activity in PCA from NP rats, but not LP rats. Structurally, 
PPARγ inhibition increased wall thickness in PCA from both NP and LP rats (p < 0.05), but 
increased distensibility only in PCA from NP rats. Pregnancy decreased expression of PPARγ 
and AT1R (p < 0.05) in cerebral arteries that was not affected by GW9662 treatment. These 
results suggest that PPARγ inhibition had significant effects on the function and structure of 
PCA in the NP state, but appeared to have less influence during pregnancy. Down-regulation 
of PPARγ and AT1R in cerebral arteries may be responsible for the lack of effect of PPARγ in 
cerebral vasculature and may be part of the vascular adaptation to pregnancy.
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  constant blood flow. Thus, it is possible that the adaptation of the 
cerebral circulation to pregnancy is to maintain normal vascular 
resistance and flow in the face of substantial changes in hemo-
dynamics in other organ systems.
Despite apparently unchanged vascular resistance and blood 
flow  in  the  brain  (Williams  and  Wilson,  1998;  Cipolla  and 
Bullinger, 2008), there are considerable changes in the cerebral 
vasculature during pregnancy. For example, endothelium-  derived 
hyperpolarizing factor-mediated dilation is lost whereas nitric 
oxide (NO) is prominent in cerebral arteries during pregnancy 
(Cipolla et al., 2004). In addition, cerebral arteries appear to adapt 
to the large amount of hormones produced during pregnancy 
as the constricting influence of pregnant plasma is normalized 
in cerebral arteries from pregnant rats (Amburgey et al., 2009). 
Further, cerebral (pial) arteries force dilatate at lower pressures 
during pregnancy (Cipolla et al., 2004). Pregnancy also appears 
to have a significant effect on hypertensive remodeling in cerebral 
vasculature. Pregnancy reverses and inhibits inward remodeling 
associated with hypertension, an effect that may maintain nor-
mal vascular resistance and blood flow during elevated blood 
pressure (Cipolla et al., 2006, 2008). Together, these adaptations 
may have an important protective role in the brain and contrib-
ute to the unchanged vascular resistance and blood flow during 
normal pregnancy.
IntroductIon
There are numerous hemodynamic changes that occur during 
pregnancy. For example, blood pressure decreases mid-pregnancy 
despite considerable expansion of blood volume and increased 
cardiac output (Gordon, 2007). The relatively low blood pressure 
in the face of increased plasma volume is likely due to reduced 
peripheral vascular resistance (Clapp and Capeless, 1997) and 
adaptation of the systemic vasculature to pregnancy that includes 
decreased  responsiveness  to  vasoconstrictors  (Parent  et  al., 
1990; Pascoal et al., 1995), decreased sympathetic vasoconstric-
tion (Ralevic and Burnstock, 1996), diminished myogenic tone 
(Learmont et al., 1996), and changes in vessel wall composition 
(Mackey et al., 1992). In addition, decreased vascular resistance 
increases blood flow in several organs during pregnancy, includ-
ing renal and uterine circulations (Palmer et al., 1992; Carlin 
and Alfirevic, 2008). However, despite substantial hemodynamic 
changes in systemic and other organs during pregnancy, vascular 
resistance and blood flow in the brain appears to be unchanged 
(Williams and Wilson, 1998; Cipolla and Bullinger, 2008). Unlike 
systemic, renal, cardiac and uterine circulations where substantial 
hemodynamic changes are essential to accommodate increased 
blood volume and flow during pregnancy, the lack of hemo-
dynamic changes in the brain is likely important in an organ 
that relies mainly on oxidative metabolism and needs relatively 
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(Coda 8 System, Kent Scientific, Torrington, CT, USA), as previously 
described (Cipolla et al., 2008). Briefly, the animals were placed 
in individual holders and both the occlusion cuff and the volume 
pressure recording cuff were secured close to the base of the tail. 
The Coda 8 system measures systolic, diastolic, and mean blood 
pressures. Blood samples were collected from the tail of conscious 
rats for blood glucose measurement on the last day of the treat-
ment, prior to euthanization (FreeStyle Lite, Abbott Inc., Alameda, 
CA, USA).
Vessel PreParatIon and PressurIzed arterIograPh system
Animals were anesthetized with isoflurane (3% in oxygen), decapi-
tated, and the brain was quickly removed and placed in cold 
HEPES-buffered physiological salt solution. A third-order branch 
of the PCA was carefully isolated and mounted on glass cannulas 
in an arteriograph chamber, the proximal cannula of which was 
connected to an in-line pressure transducer and a   servo-null pres-
sure control system (Living Systems Instrumentation, Burlington, 
VT,  USA).  The  distal  cannula  was  closed  during  the  experi-
ment to avoid flow-mediated responses. Temperature and pH 
were continually measured and maintained at 37.0 ± 0.5°C and 
7.40 ± 0.05, respectively. Measurements of inner diameter (ID) 
and wall thickness (WT) were made via video microscopy (Living 
Systems Instrumentation, Burlington, VT, USA). The remaining 
cerebral pial vessels were dissected from the brain, collected in 
RNAlater (Qiagen Inc, Valencia, CA, USA) and rapidly frozen for 
PCR analysis.
exPerImental Protocol
Arteries were equilibrated for 1 h at 25 mmHg. Active myogenic 
activity  was  determined  by  stepwise  increases  in  pressure  (in 
25 mmHg increments) from 25 to 175 mmHg and ID measured 
at each pressure. To obtain agonist-induced vasodilatory responses, 
pressure was returned to 75 mmHg until tone developed and 
diameter stabilized. Arteries were then exposed to cumulative con-
centrations of ACh (10−8–10−5 M) and ID recorded at each concen-
tration once stable. ACh was then washed from the bath and SNP 
(10−8–10−5 M) was cumulatively added and ID recorded. To obtain 
structural measurements, ID and WT were recorded at pressures 
between 5 to 175 mmHg after papaverine (10−4 M) and diltiazem 
(10−5 M) were added to the bath to fully relax smooth muscle.
real-tIme rt-Pcr analysIs of target genes In PIal Vessels
Gene expression of PPARγ and AT1R were determined in cer-
ebral  vessels  using  standard  techniques  for  real-time  RT-PCR, 
as described previously (Cipolla et al., 2009). These procedures 
were performed by the DNA facility at the University of Vermont. 
Results were calculated by the 2−∆∆CT method (Livak and Schmittgen, 
2001). The percent change in gene expression was normalized to 
an endogenous gene (β2-microglobulin, B2M) and relative to the 
untreated NP group.
drugs and solutIons
ACh, SNP, papaverine, and diltiazem were purchased from Sigma 
(St. Louis, MO, USA). Drugs were made as stock solutions each 
week and stored at 4°C. GW9662 was purchased from Cayman 
Chemical  (Ann Arbor,  MI,  USA). All  vessel    experiments  were 
Although it appears the cerebral circulation adapts to   pregnancy, 
the  underlying  mechanism  by  which  this  occurs  is  not  clear. 
Peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear 
receptor transcription factor, regulates the transcription of tar-
get genes involved in adipogenesis, glucose homeostasis, and lipid 
metabolism (Berger et al., 2005). The role of PPARγ has also been 
implicated in pregnancy. PPARγ is highly activated during preg-
nancy (Waite et al., 2005) and has an important role in maternal 
metabolism,  placental  development,  and  trophoblast  invasion 
(Wieser et al., 2008). Recently, the pleiotropic effect of PPARγ 
has been shown in the cardiovascular system. PPARγ appears to 
have direct protective effects including anti-hypertensive, anti-
  inflammatory, and anti-atherosclerotic properties in the vascula-
ture (Hsueh and Law, 2001; Robinson and Grieve, 2009; Sigmund, 
2010). These protective effects of PPARγ may be more prominent in 
the cerebral circulation. For example, genetic interference of PPARγ 
function reduced the vasodilatory response to ACh in basilar arter-
ies, but not in aorta (Beyer et al., 2008). The same study also showed 
that interference of PPARγ function causes hypertrophic inward 
remodeling, suggesting that inhibiting structural remodeling may 
also be a protective effect of PPARγ in cerebral vasculature. Thus, 
the role of PPARγ in the cerebral circulation appears similar to 
that of pregnancy, including enhanced NO-dependent dilation and 
inhibition of structural remodeling. Considering PPARγ is highly 
activated during pregnancy, we hypothesized that PPARγ activity 
is involved in the vascular adaptation to pregnancy in the cerebral 
circulation. To test this hypothesis, pregnant and non-pregnant 
(NP) rats were treated with GW9662, a specific PPARγ inhibitor 
that acts through cysteine modification in the ligand-binding site of 
PPARγ (Leesnitzer et al., 2002). We investigated the effect of PPARγ 
inhibition during pregnancy on NO-mediated dilation, myogenic 
activity, and structural characteristics of posterior cerebral arteries 
(PCA). In addition, gene expression of PPARγ and angiotensin type 
1 receptor (AT1R) were determined in cerebral arteries because of 
the potential involvement of these receptors in vascular function 
and remodeling during pregnancy (Cox et al., 1996).
materIals and methods
anImals and treatment grouPs
Pregnant (6–8 days pregnant) and NP (12–14 weeks old) Sprague 
Dawley rats (Charles River, Canada) were housed in the University 
of Vermont Animal Care Facility. Animals were randomly selected 
and treated with either GW9662 (10 mg/kg/day for 10 days in food; 
n = 8) or vehicle (n = 8). This dose of GW9662 was higher than 
has been reported in other studies (Sivarajah et al., 2005) due to 
the higher activation of PPARγ in pregnancy (Waite et al., 2000). 
Rats were studied on day 20 or 21 of pregnancy. There was one NP 
rat that did not consume GW9662, and thus was excluded from 
the study and all comparisons. All procedures were approved by 
the Institutional Animal Care and Use Committee and conducted 
in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals.
Blood Pressure and glucose measurements
Blood pressures were measured non-invasively every 2–3 days 
during GW9662 treatment by determining the tail blood volume 
with a volume pressure recording sensor and an occlusion tail cuff www.frontiersin.org  August 2010  | Volume 1  | Article 130  |  3
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active    myogenic  activity  that  was  sustained  until  175  mmHg 
(Figures 2A,B). At 175 mmHg, there was a dramatic increase in ID 
as arteries underwent forced dilatation. PCA from GW9662-treated 
NP rats had smaller ID at all pressures when compared to untreated 
NP rats, although this was not statistically significant (Figure 2A). 
The decreased ID was particularly obvious at 75 and 100 mmHg 
(decreased  by  23%  and  24%,  respectively)  when  compared  to 
untreated NP rats. This smaller ID may be due to increased tone by 
GW9662 treatment. In contrast to NP rats, GW9662 treatment did 
not decrease ID, but rather tended to increase ID of PCA at all pres-
sures from LP rats, although this was not statistically significant.
effects of gW9662 durIng Pregnancy on ach- and  
snP-Induced dIlatIon
In the GW9662-treated NP group, four experiments were excluded 
because there were three PCA that either did not develop basal tone 
or maximally dilated prematurely during ACh exposure. In addition, 
there was one PCA in each untreated NP and LP group that did not 
develop tone, and thus were excluded. These explain the inconsistent 
and low number in GW9662-treated NP group (n = 4).
Figure 3A shows the concentration-response relationship of 
ACh-induced dilation. GW9662 inhibited ACh-induced dilation 
in PCA from NP rats but did not affect the response to ACh in 
PCA from LP rats. Two-way ANOVA revealed that dilator responses 
to ACh (from 3 × 10−7 to 10−5 M) in PCA from NP-GW rats were 
significantly different from that of LP-GW rats. This difference was 
likely due to absence of dilation to ACh in PCA from NP-GW rats 
because GW9662 did not impact ACh-induced dilation in PCA 
from LP rats.
Figure 3B shows the concentration-response of SNP-induced 
dilation for all groups of animals. GW9662 treatment decreased the 
dilator response to SNP in PCA from NP rats, although this was not 
statistically significant, likely due to the small sample size in NP-GW 
group. Similar to the dilator response to ACh,   two-way ANOVA 
  performed in physiological salt solutions containing the   following 
(in mM): 142.0 NaCl, 4.7 KCl, 1.2 MgSO4, 0.5 EDTA, 2.8 CaCl2, 
10.0 HEPES, 1.2 KH2PO4, and 5.0 glucose.
data calculatIons and statIstIcal analysIs
Percent tone was calculated as percent decrease in ID from the 
passive  diameter  at  each  intravascular  pressure:  [1  −  (IDactive/
IDpassive)]  ×  100%.  Outer  diameter  (OD)  was  calculated  from 
  measured ID and WT: ID + 2WT. Wall-to-lumen ratio was   calculated 
as: ID/WT. Cross-sectional area (CSA) of the wall was calculated as: 
[(0.5 × OD)2 − (0.5 × ID)2] × π. Passive   distensibility was calculated 
as the percent change in ID at a given pressure (IDp) from the origi-
nal diameter (IDo, at 5 mmHg): [(IDp − IDo)/IDo] × 100%.
All data are presented as mean ± SEM. Differences between 
individual groups were compared with one-way analysis of vari-
ance (ANOVA) with post hoc Student–Newman–Keuls Multiple 
Comparison Test, using Graph Pad Prism 5 (Graph Pad Software 
Inc., La Jolla, CA, USA). It was anticipated that pregnancy would 
alter responses to GW9662, thus two-way ANOVA was used to 
compare two independent variables GW9662 treatment and preg-
nancy, and their interaction. Differences were considered significant 
when p < 0.05.
results
PhysIologIcal Parameters
Physiological parameters for all groups of animals are shown in 
Table 1. Pregnancy significantly decreased blood glucose compared 
to the untreated NP group. GW9662 increased blood glucose in 
NP rats but had no effect on late-pregnant (LP) rats. Pregnancy 
decreased mean arterial pressure compared to untreated NP rats. 
GW9662 treatment decreased mean arterial pressure in NP rats, 
but did not further affect blood pressure in LP rats. As expected, 
body weights were significantly increased in LP rats. GW9662 did 
not affect body weights of either NP or LP rats.
effects of gW9662 durIng Pregnancy on tone and myogenIc 
actIVIty
Figure 1 shows percent tone in PCA at 75 mmHg from all groups. 
GW9662 treatment tended to increase tone in PCA from NP rats 
(44 ± 3% vs. 30 ± 6% in control, p = 0.08), but had no effect in PCA 
from LP rats. Figure 2 shows active internal diameters versus intra-
luminal pressure for all groups of animals. Most PCA constricted 
when pressure increased from 25 to 75 mmHg,   demonstrating 
Table 1 | Physiological parameters of non-pregnant (NP), NP treated 
with GW9662 (NP + GW), late-pregnant (LP), and LP treated with 
GW9662 (LP + GW).
  NP (n = 8)  NP + GW  LP (n = 8)  LP + GW 
   ( n = 7)    (n = 8)
Body weights (g)  308 ± 4  306 ± 5  384 ± 7*  381 ± 5*
Blood glucose (mg/dl)  109 ± 3  132 ± 9*  88 ± 5*  91 ± 4†
Mean arterial  105 ± 3  92 ± 4*  92 ± 4*  87 ± 3* 
pressure (mmHg)
Data are presented as means ± SEM.
*p < 0.05 vs. NP; †p < 0.05 vs. NP + GW.
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FiGure 1 | Graph showing percent tone of PCA at intraluminal pressure 
of 75 mmHg from non-pregnant (NP), NP treated with the PPArγ 
inhibitor GW9622 (NP + GW), late-pregnant (LP), LP treated with GW9662 
(LP + GW). PPARγ inhibition tended to increase tone in NP-GW rats (p = 0.08), 
but had no effect on pregnant rats.Frontiers in Physiology  |  Vascular Physiology    August 2010  | Volume 1  | Article 130  |  4
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increased  in  PCA  from  GW9662-treated  NP  rats  (Table  2). 
Compared to untreated NP rats, PCA from NP-GW rats had only 
a small decrease in ID. Thus, the increased WT was the major con-
tributor to the increased wall-to-lumen ratio. GW9662-induced 
hypertrophy in PCA from NP rats was confirmed by increased 
CSA. Moreover, similar increases in WT were observed in PCA 
from LP-GW rats with increased wall-to-lumen ratio and CSA. 
Two-way ANOVA revealed that GW9662 treatment significantly 
altered WT, wall-to-lumen ratio, and CSA compared to untreated 
NP and LP rats. Compared to untreated LP rats, hypertrophy in 
PCA from LP-GW rats contributed to an increase in OD because 
ID was similar. These results suggest that PPARγ inhibition caused 
inward hypertrophic remodeling in PCA from NP rats, but outward 
hypertrophic remodeling in PCA from LP rats.
revealed that dilator responses to SNP (from 10−7 to 10−5 M) in 
PCA from NP-GW rats were significantly different from that of 
LP-GW rats. Dilation to SNP in PCA from NP-GW rats was the 
main contributor to the difference, because GW9662 did not affect 
dilation to SNP in PCA from LP rats.
effects of gW9662 durIng Pregnancy on Vascular  
structure In Pca
To examine structural changes of PCA in response to pregnancy and 
GW9662 treatment, we measured ID and WT in fully relaxed PCA 
(by papaverine and diltiazem) at 5 mmHg. Measurements were 
made at minimal pressure (5 mmHg) to avoid vessel collapse and 
eliminate differences due to changes in distensibility. OD, wall-to-
lumen ratios, and CSA were also calculated. WT was   significantly 
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FiGure 2 | Graph showing active internal diameters versus intraluminal 
pressure of PCA in (A) non-pregnant (NP) and GW9662-treated NP 
(NP + GW) groups; (B) late-pregnant (LP) and GW9662-treated LP (LP + GW) 
groups. Myogenic activity in PCA was demonstrated by constriction in response 
to increases in pressure and tended to be increased in NP-GW but not in PCA 
from LP or LP-GW rats.
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FiGure 3 | Graph showing percent dilation of PCA in response to (A) ACh 
(10−8–10−5 M) and (B) SNP (10−8–10−5 M) from non-pregnant (NP), NP treated 
with the PPArγ inhibitor GW9622 (NP + GW), late-pregnant (LP), LP treated 
with GW9662 (LP + GW). Note that two-way ANOVA revealed that dilation to 
ACh (3 × 10−7–10−5 M) and SNP (10−7–10−5 M) in PCA from NP + GW rats was 
significantly different from that of LP + GW rats. *p < 0.05 vs. LP + GW.www.frontiersin.org  August 2010  | Volume 1  | Article 130  |  5
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To further examine structural changes of the vessel wall in 
response to pregnancy and GW9662 treatment, we calculated pas-
sive distensibility at various intraluminal pressures. Figure 4 shows 
passive distensibility from all groups of animals. GW9662 treatment 
significantly increased distensibility at pressures of 30, 40, 50 mmHg 
in PCA from NP rats (Figure 4A) but did not affect distensibility of 
PCA from LP rats (Figure 4B). In addition, compared to NP rats, 
distensibility was increased at 30, 40, 50, 75 mmHg in PCA from LP 
rats (Figure 4C). The effect of GW9662 treatment on distensibility 
was similar in PCA from NP and LP rats (Figure 4D).
effects of gW9662 and Pregnancy on target gene exPressIon
Relative mRNA expression of PPARγ in cerebral vessels was signifi-
cantly decreased during pregnancy regardless of GW9662 treatment 
(Figure 5A). GW9662 did not change the expression of PPARγ in 
cerebral vessels from NP or LP rats. Messenger RNA expression of 
AT1R expression was significantly decreased in cerebral vessels from 
LP rats, but was also unaffected by GW9662 treatment in cerebral 
vessels from NP or LP rats (Figure 5B).
Table 2 | Passive structural measurements of cerebral posterior arteries 
in non-pregnant (NP), NP treated with GW9662 (NP + GW), late-
pregnant (LP), and LP treated with GW9662 (LP + GW) at 5 mmHg.
  NP (n = 8)  NP + GW  LP (n = 8)  LP + GW 
   ( n = 7)    (n = 8)
Inner diameter  127 ± 5  117 ± 2  121 ± 3  121 ± 4 
(μm)
Outer diameter 168 ± 5  166 ± 2  164 ± 4  170 ± 5 
(μm)
Wall thickness  20.5 ± 0.8  24.3 ± 0.8*  21.9 ± 0.9  24.1 ± 1.1* 
(μm)
Wall-to-lumen  0.162 ± 0.008 0.208 ± 0.009* 0.182 ±  0.008 0.199 ± 0.008* 
ratio
CSA (μm2)   9542 ± 535  10786 ± 355*  9817 ± 569  11093 ± 736*
Data are presented as means ± SEM.
CSA, cross-sectional area.
*p < 0.05 vs. NP .
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FiGure 4 | Graph showing passive distensibility versus intraluminal pressure of PCA in (A) non-pregnant (NP) and GW9662-treated NP (NP + GW) groups; 
(B) late-pregnant (LP) and GW9662-treated LP (LP + GW) groups; (C) NP and LP groups; and (D) NP + GW and LP + GW groups. *p < 0.05: NP vs. NP + GW; 
†p < 0.05: NP vs. LP .Frontiers in Physiology  |  Vascular Physiology    August 2010  | Volume 1  | Article 130  |  6
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may still be activated during pregnancy even in the presence of 
GW9662. Relaxin, a hormone circulating at high concentration 
during pregnancy, has been shown to activate PPARγ through a 
non-receptor-mediated mechanism (Singh and Bennett, 2010). 
Thus, it is possible that other non-receptor-mediated effects of 
PPARγ may still be present because GW9662 only inhibited recep-
tor-mediated actions of PPARγ.
PPARγ has been shown to have a significant beneficial role in 
protecting the vasculature, especially with regards to endothelial 
function. Genetic interference with PPARγ function has been shown 
to decrease ACh-induced dilation in cerebral vessels of male mice 
(Beyer et al., 2008), suggesting PPARγ activity is important for 
normal endothelial function in the cerebral circulation. In the 
present study, PPARγ inhibition with GW9662 treatment decreased 
ACh and SNP dilation in PCA from NP rats, which is in partial 
agreement with a previous study (Beyer et al., 2008). Although 
this previous study did not find an effect of PPARγ on dilation 
to SNP, another study has shown that interference with PPARγ 
decreased dilation to SNP in aorta (Halabi et al., 2008). Together, 
these results suggest that PPARγ inhibition with GW9662 impacts 
NO-mediated dilation in both endothelium and smooth muscle in 
males and NP females. However, NO responsiveness was unaffected 
when PPARγ was inhibited during pregnancy, possibly due to a 
pregnancy-specific adaptation such as decreased PPARγ expression 
or a difference in treatment efficacy.
An important function of cerebral arteries is that they con-
strict or dilate in response to increases or decreases in pressure, 
respectively. This myogenic activity is well-developed in the brain 
circulation and underlies autoregulation of cerebral blood flow 
(Johnson, 1989). In the present study, we tested how PPARγ inhibi-
tion during pregnancy affected tone and myogenic activity in PCA. 
Pregnancy alone did not change basal tone in PCA at physiologi-
cal pressures (75 mmHg), which is similar to our previous study 
(Cipolla et al., 2004). PPARγ inhibition tended to increase tone in 
PCA from NP rats, but not in PCA from LP rats. The increased tone 
in NP-GW rats may be due to reduced endothelium-dependent 
dIscussIon
There are several novel findings in the present study. First, PPARγ 
inhibition with GW9662 abolished dilation to ACh and reduced 
the dilatory response to SNP in PCA from NP rats, suggesting that 
PPARγ inhibition may cause endothelial dysfunction and reduced 
smooth muscle responsiveness to NO. However, PPARγ inhibition 
had no effect on the dilation to ACh and SNP in PCA from LP 
rats. Second, PPARγ inhibition tended to increase basal tone and 
myogenic activity in PCA from NP rats. These effects were not 
seen in PCA from LP rats. Third, PPARγ inhibition increased WT, 
wall-to-lumen ratio, CSA, and passive distensibility in PCA from 
NP rats. A small decrease in ID was associated with increased WT, 
suggesting inward remodeling in these vessels. PPARγ inhibition 
also increased WT and CSA in PCA from LP rats. However, a small 
increase in OD was observed in these vessels, suggesting outward 
remodeling. Lastly, gene expression of PPARγ and AT1R in cerebral 
vessels were decreased in LP rats regardless of GW9662 treatment. 
In summary, PPARγ inhibition caused vascular dysfunction and 
inward remodeling in cerebral arteries from NP animals, but had 
little effect during pregnancy except to promote modest outward 
remodeling.
There may be several reasons why GW9662 treatment had little 
effect on physiological parameters and vascular function in PCA 
from LP rats. First, pregnancy significantly decreased (by 85%) 
gene expression of PPARγ, regardless of GW9662 treatment. It is 
therefore possible that further inhibition of PPARγ that was already 
highly  down-regulated  during  pregnancy  was  not    efficacious. 
Second, it is possible that treatment with GW9662 during preg-
nancy was too mild to have a significant effect. Because we were 
concerned about PPARγ inhibition interfering with implantation 
and establishment of pregnancy, we treated animals during the 
second half of pregnancy. PPARγ inhibition may have had a greater 
influence if treatment with GW9662 was started in early pregnancy 
or even prior to pregnancy. In addition, the dose of GW9662 used 
may not have been high enough to inhibit PPARγ in late-pregnancy 
when PPARγ is highly activated (Waite et al., 2005). Lastly, PPARγ 
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FiGure 5 | Graph showing relative changes in mrNA expression of 
(A) PPArγ and (B) angiotensin type 1 receptors (AT1r) in cerebral vessels of 
non-pregnant (NP), NP + GW9662 (NP + GW), late-pregnant (LP), and 
LP + GW9662 (LP + GW) groups. Results are presented as percent change in 
gene expression normalized to β2-microglobulin (B2M), an endogenous 
reference gene, and relative to the untreated NP group (n = 7–8, mean ± SEM). 
Expression of PPARγ and AT1R was decreased in cerebral vessels from LP rats 
but unaffected by GW9662 treatment.*p < 0.05 vs. NP , †p < 0.05 vs. NP + GW.www.frontiersin.org  August 2010  | Volume 1  | Article 130  |  7
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In conclusion, PPARγ inhibition appears to have little impact 
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nancy. This lack of an effect of PPARγ inhibition in cerebral vascu-
lature may be due, at least in part, to down-regulation of PPARγ and 
AT1R in cerebral arteries during pregnancy. Changes in expression 
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vasodilator production as ACh responses were abolished in those 
animals, however, we did not directly examine the effect of PPARγ 
inhibition on basal endothelial vasodilator release. In addition, as 
dilation to SNP was also decreased in PCA from NP-GW rats, it is 
possible that the smooth muscle response to vasodilator was also 
affected by PPARγ inhibition. In addition, PCA from all groups 
developed myogenic activity as demonstrated by active constric-
tion in response to increases in pressure. Pregnancy did not sig-
nificantly change myogenic activity within the myogenic pressure 
range, which agrees with our previous study (Cipolla et al., 2004). 
Moreover, PPARγ inhibition with GW9662 appeared to increase 
myogenic activity at lower pressures (50, 75 mmHg) in PCA from 
NP rats, but did not seem to affect myogenic activity from LP rats. 
Although PPARγ appeared to be involved in regulating tone and 
myogenic activity in the NP state possibly through endothelium 
or smooth cell effects, the results from the present study suggest 
that PPARγ appears to have little effect on basal tone and myogenic 
activity in cerebral vasculature during pregnancy.
One of the most profound influences of PPARγ in the vasculature 
is on structural remodeling. Some studies have shown that PPARγ 
is involved in vascular remodeling in cerebral vessels in male rats 
(Beyer et al., 2008; Halabi et al., 2008). Pregnancy also has a signifi-
cant effect in cerebral artery remodeling, especially during hyper-
tension, that is similar to those attributed to PPARγ. For example, 
hypertension can cause inward remodeling in the cerebral vascu-
lature (Baumbach et al., 1988) and pregnancy has been shown to 
both prevent and reverse hypertensive remodeling in PCA (Cipolla 
et al., 2006, 2008). In a recent study, similar prevention of hyper-
tensive remodeling of PCA from NP rats was shown in response 
to PPARγ activation (Cipolla et al., 2010). In the present study, we 
determined if PPARγ activity during pregnancy impacted structural 
remodeling in cerebral arteries. PPARγ inhibition caused hypertro-
phy in PCA from both NP and LP rats, as evidenced by increased 
WT and CSA. These results suggest that PPARγ may have a role in 
suppressing smooth muscle growth and migration (Meredith et al., 
2009). Interestingly, the remodeling in PCA from NP rats appeared 
to be different from that of PCA from LP rats. For example, PPARγ 
inhibition caused inward hypertrophic remodeling in PCA from 
NP rats but outward hypertrophic remodeling in PCA from LP 
rats. The differential response to PPARγ inhibition in NP and LP 
rats is not clear, but may involve pregnancy-induced decrease in 
AT1R in the cerebral vasculature. Angiotensin II has a significant 
role in remodeling in cerebral vasculature (Baumbach et al., 2003; 
Dupuis et al., 2005) through NADPH oxidase-derived superoxide 
and not hypertension per se (Chan and Baumbach, 2009). This 
effect of angiotensin II is largely through the activation of AT1R 
(Griendling et al., 1997). A previous study showed that inward 
remodeling of cerebral arterioles induced by interference with 
PPARγ function involved increased superoxide (Beyer et al., 2008). 
Moreover, PPARγ activation suppresses AT1R in vascular smooth 
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